Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
AbbVie buys Syndesi for neuroscience compound
by Michael McCoy
March 6, 2022
| A version of this story appeared in
Volume 100, Issue 9
AbbVie has acquired neuroscience drug developer Syndesi Therapeutics for $130 million and milestone payments of up to $870 million. Syndesi was founded in 2017 to develop modulators of synaptic vesicle protein 2A, which plays a role in regulating neurotransmission. The modulators, including Syndesi’s lead compound SDI-118, were discovered by UCB. AbbVie says it plans to advance SDI-118, which is now in Phase 1b clinical trials.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter